The FDA requires follow-up studies for drugs and devices. Years later, many still aren’t done
An analysis of FDA data found hundreds of postmarket studies running behind schedule, raising questions about the agency’s ability to ensure manufacturers follow through.
An analysis of FDA data found hundreds of postmarket studies running behind schedule, raising questions about the agency’s ability to ensure manufacturers follow through. This story matters for Government & Civic readers tracking council. Reported by govexec.com. Read the full original at the source link below.
Originally reported by govexec.com. CouncilNews curates and briefs the government & civic stories that matter. Our editorial policy →